EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor

Arun R K Kumar iD, Crystal Sara Shaji, Aswathi Rajagopalan, Sombodhi Bhattacharya, Wilner Martínez-López, Radha Saraswathy iD

PLOS One · 2026

DOI: 10.1371/journal.pone.0340472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Arun R K Kumar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Genetics Research Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Etoposide, Breast Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vellore Institute of Technology (VIT) Seed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains the leading cause of cancer-related deaths in women. Therefore, developing targeted combination therapies that improve overall survival in breast cancer patients continues to pose a major clinical challenge. Etoposide (ETO), a topoisomerase II inhibitor that induces transient double-strand breaks by blocking the cleavable complex, is currently used in high doses to treat radioresistant or metastatic breast cancers. To enhance the effectiveness of radiation and chemotherapy, targeting molecular mechanisms involved in DNA repair of induced DNA lesions could selectively increase tumor cell death. Since the effects of ETO are primarily seen during the S/G2 phases of the cell cycle, its efficacy could potentially be enhanced by using an inhibitor of a DNA repair gene involved in homologous recombination, which is mainly active during these phases. In this context, synthetic lethality refers to the concept that inhibiting or mutating two or more genes simultaneously leads to greater cell death than altering them individually. The FDA approval of Olaparib, a specific PARP inhibitor for BRCA-mutated breast cancer patients, has motivated researchers to explore other synthetic lethal interactions that could increase DNA damage accumulation, leading to cancer cell death. We demonstrate that successive treatment of breast cancer cells with specific inhibitors of ATM kinase and topoisomerase II in vitro can induce increased apoptosis. ATM is an apical kinase that recognizes DNA double-strand breaks and activates the homologous recombination repair pathway, either directly or through cell cycle checkpoint control. Topoisomerase II poisons generate enzyme-mediated DNA damage, leading to permanent double-strand breaks. Cytokinesis-block micronucleus assay was performed to assess the increase in DNA damage during combination treatment with inhibitors. Additionally, cell viability tests and fluorescent staining assay were conducted to evaluate the extent of cell death. We found that targeting ETO-treated breast cancer cells with an ATM kinase inhibitor, KU-55933 (KU) induced higher chromosomal damage/aberrations, as evaluated by the cytokinesis-block micronucleus assay. The ATM kinase inhibitor also significantly reduced the viability of ETO-treated breast cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsEtoposideBreast NeoplasmsHumansFemaleCell Line, TumorTopoisomerase II InhibitorsPiperazinesPyronesMorpholinesPhthalazinesDNA Breaks, Double-Stranded

Substanzen

Ataxia Telangiectasia Mutated ProteinsEtoposideATM protein, human2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-oneTopoisomerase II InhibitorsPiperazinesPyronesMorpholinesPhthalazinesolaparib

Autor:innen und Institutionen

  • Biomedical Genetics Research Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, India.
  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Genetics Department and Biodosimetry Service, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay.

ORCID-Profile: Arun R K Kumar, Radha Saraswathy

Förderung

  • Vellore Institute of Technology (VIT) Seed

Zitieren

APA

Kumar, A. R. K., Shaji, C. S., Rajagopalan, A., Bhattacharya, S., Martínez-López, W., & Saraswathy, R. (2026). Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor. PLOS One. https://doi.org/10.1371/journal.pone.0340472

Vancouver

Kumar ARK, Shaji CS, Rajagopalan A, Bhattacharya S, Martínez-López W, Saraswathy R. Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor. PLOS One. 2026. doi:10.1371/journal.pone.0340472

BibTeX
@article{Kumar2026,
  author = {Kumar, Arun R K and Shaji, Crystal Sara and Rajagopalan, Aswathi and Bhattacharya, Sombodhi and Martínez-López, Wilner and Saraswathy, Radha},
  title = {Increased sensitivity of etoposide-treated breast cancer cells with an ATM inhibitor},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0340472}
}
Kostenlos starten →